HANSOH PHARMA (03692.HK): Class 1 Innovative Drug HS-20197 for Injection Receives Clinical Trial Approval Notice, Intended for Advanced Solid Tumours
- The drug is a Class 1 innovative drug independently developed by the Group.
- The drug clinical trial approval notice was issued on 11 September 2026.
NewTimeSpace News: On 16 September 2026, Hansoh Pharmaceutical Group Company Limited (stock code: 03692.HK) announced that on 11 September 2026, HS-20197 for injection, a Class 1 innovative drug independently developed by the Group, obtained a drug clinical trial approval notice issued by the National Medical Products Administration (NMPA) of the PRC, for the conduct of clinical trials in "advanced solid tumours".
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- HANSOH PHARMA (03692.HK): Small Cell Lung Cancer Product HS-20093 Included in NMPA Priority Review Procedure
- HANSOH PHARMA (03692.HK): NDA for HS-20093 in Small Cell Lung Cancer Accepted by NMPA
- HK Stock Connect Daily Report: ZJ INNOLIGHT Officially Added to Stock Connect, Z.AI Surges Over 12%, Southbound Net Buying Reaches HKD 3.18 Billion - 20260827
- HANSOH PHARMA(03692.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at CNY 4.26 billion, YoY increase of 35.82%
- HANSOH PHARMA (03692.HK): Self-Developed Class 1 New Drug HS-10582 Tablet Receives NMPA Clinical Trial Approval Notice for Primary Hypercholesterolemia
